Нашел абстракт этой статьи. Посмотрим, что покажет более широкое исследование
Results: RVR was achieved in 18 (66.7%) subjects (6/12, 6/6, 6/8 for group 1, 2, 3 respectively, p = 0.06). Baseline viral load was lower in subjects with RVR as compared to those without RVR (log10 IU/mL 5.96 vs. 7.00, p<0.0001). The median time to achieve plasma HCV RNA < 25 IU/mL (limit of detection) was shorter in group 1 as compared to group 3 (p = 0.01 ). All18 subjects who had RVR and 3 weeks DAAs achieved SVR12. There were no discontinuations or significant adverse events reported. Conclusions: This proof-of-concept SODAPI study explored RGT to shorten the duration of HCV treatment. The results strongly suggest that administration of potent triple regimens containing NS3, NS5A and NS5B HCV-inhibitors leads to RVR (plasma HCV RNA < 500 IU/mL) within 2 days in two-thirds of non-cirrhotic HCV GT 1 b-infected subjects. 100% of subjects with RVR and had treatment for 3 wks, achieved SVR12,with excellent adherence and tolerability. Future studies exploring this RGT concept are recommended to reduce duration of therapy, cut drug costs, and to significantly improve accessibility and adherence. (CiinicaiTrials.gov number NCT02470858)
ff895's post in Ученые Создали Сверхбыстрое Лекарство От Гепатита С was marked as the answer
